Synthetic Biology: Twist Bioscience Revenue Growing From $2 To $200 Million As It Eyes The $186 Billion Antibody Market

  • 📰 ForbesTech
  • ⏱ Reading Time:
  • 79 sec. here
  • 3 min. at publisher
  • 📊 Quality Score:
  • News: 35%
  • Publisher: 59%

Business News News

Business Business Latest News,Business Business Headlines

The biggest reason why Twist is currently valued at $1.9 billion is the potential to use their silicon DNA synthesis platform for the discovery of new drugs.

to bolster its capability for antibody discovery and characterization in animals. This acquisition complements the already existing platform for animal-free antibody discovery and machine-learning approaches led by Aaron Sato’s team.

“Our role in the [SynBio] community is to serve and leverage the scale of the Twist synthesis platform to enable more discovery and optimization,” Patrick Finn commented on the direction that the company is developing in. “Where Twist is exceptional is that we listen to the market and follow opportunities where our technology aligns with what the market needs.” With the company quickly outgrowing its current niche, Patrick’s role will be to help it scale.

"I am super excited to have Paddy as our President and COO. He's driven our revenue growth quarter over quarter, adding customers and product lines. One of the things that Paddy brings to this new position, that is not only responsible for commercial but also operations, is customer-centricity. I believe he will be a great force of growth for Twist,” said the CEO.

Twist is, in fact, scaling quite literally: the company is opening a new facility outside of Portland, Oregon, which is set to start shipping its first product in January 2023. Tracey Mullen, who was the CEO of Abveris at the time of acquisition, is leading the effort to build the “Factory of the Future” in her new role as VP of Operations.

“The volume of the products coming out of our facilities is enormous,” says Patrick. He sees the company’s core platform as an essential driver for the rapidly expanding biotech industry with applications in healthcare, industrial chemicals, agriculture, and academic research. “Bringing our technology up to scale will enable us to drive profitability in business.”

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

I read.Twist CEO Emily Leproust rang the bell on its opening day on the Nasdaq, and the company’s revenue has been growing steadily since the IPO. Twist reported its record earnings of $56.1 million for the fiscal third quarter of 2022, a 60% increase compared to $35.0 million..

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 318. in BUSİNESS

Business Business Latest News, Business Business Headlines